Reported Saturday, Boston Scientific's CHAMPION-AF Trial Of Watchman FLX Device Meets All Primary And Secondary Endpoints, Delivering 45% Relative Reduction In Non-Procedural Bleeding Versus NOAC

Boston Scientific's CHAMPION-AF trial for the WATCHMAN FLX device achieved all primary and secondary endpoints, showing a 45% relative reduction in non-procedural bleeding compared to NOACs. The device provided statistically superior protection from bleeding while demonstrating similar efficacy to blood thinners in patients with non-valvular atrial fibrillation. These findings were presented at ACC.26 and published in The New England Journal of Medicine.